Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Orforglipron showed clinically meaningful results at 72 weeks, after three doses, in a pool of more than 3000 adults.

Ozempic is linked to a potentially higher risk of vision loss in some studies. Doctors explain how GLP-1 drugs for diabetes ...

Mounjaro manufacturer Eli Lilly has unveiled the test results of its new oral GLP-1 medication, orforglipron. The obesity pill, which is designed to be taken daily by patients who are severely ...

Are weight loss shots like Ozempic and Wegovy safe long-term? It’s complicated. Some early studies suggest thyroid concerns ...

GLP-1 receptor agonists are associated with risk reductions for dozens of diseases and conditions in addition to rapid weight ...

A chip addict who ballooned to 280 pounds scoffing down four bags a day managed to lose half her body weight naturally — ...

It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting ...

Users of weight loss drugs such as Wegovy and Mounjaro, along with those who use type 2 diabetes drug Ozempic for weight loss ...

By taking 36 mg once per day - without food and water restrictions - participants lost an average of 12.4 percent of their body weight - about 27.3 pounds (12.4 kilograms). This was over the span of ...

Whatever your thoughts on weight-loss injections, their rise shows no signs of slowing. And now a Dubai restaurant has become ...

People taking the new wonder drug orforglipron lost an average of 12.4 per cent of their body weight after 72 weeks and ...